Progenics

United States Founded: 1988 • Age: 38 yrs Acquired By Lantheus
Imaging compounds targeted radiotherapies to detect and treat prostate cancer.
Request Access

About Progenics

Progenics is a company based in United States founded in 1988 was acquired by Lantheus in October 2019.. The company has 53 employees as of December 31, 2020. Progenics has completed 3 acquisitions, including AZEDRA, EXINI Diagnostics and Molecular Insight Pharmaceuticals. Progenics operates in a competitive market with competitors including ImaginAb, MDxHealth, AC Immune, GenomeDx Biosciences and APRINOIA, among others.

  • Headquarter United States
  • Employees 53 as on 31 Dec, 2020
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Progenics Pharmaceuticals, Inc.
Operational Areas
Healthcare → Medical Devices & Diagnostics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
    $12.92 M (USD), Post-IPO

    Jan 18, 2013

  • Investors
    HHS

    & 1 more

  • Employee Count
    53

    as on Dec 31, 2020

  • Investments & Acquisitions
    AZEDRA

    & 2 more

  • Acquired by
    Lantheus

    (Oct 02, 2019)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of Progenics
Headcount 50-200
Employee Profiles 12
Employee Profiles
People
Asha Das
Chief Medical Officer
People
David W. Mims
Intermin CEO
People
Vivien Wong
Executive Vice President, Development
People
Jason Perez
Manager, Lab operations

Unlock access to complete

Funding Insights of Progenics

  • Total Funding
  • Total Rounds 8
  • Last Round Post-IPO — $12.9M
  • First Round

    (01 Jan 2006)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Jan, 2013 Amount Post-IPO - Progenics Valuation

investors

May, 2011 Amount Grant - Progenics Valuation

investors

HHS
Sep, 2010 Amount Grant - Progenics Valuation

investors

HHS
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Progenics

Progenics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Lantheus. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Public health and human services are overseen by HHS.
Founded Year Domain Location
Developer of diagnostic imaging agents and targeted therapeutics
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Progenics

Progenics has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include AZEDRA, EXINI Diagnostics and Molecular Insight Pharmaceuticals. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Therapy for pheochromocytoma and paraganglioma diseases is provided.
2006
Artificial neural networks are applied to medical scan diagnostics.
1999
Radiopharmaceuticals and molecular imaging agents for use in oncology
1997
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Progenics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Progenics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Progenics

Progenics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ImaginAb, MDxHealth, AC Immune, GenomeDx Biosciences and APRINOIA, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
ImaginAb is focused on developing advanced immuno-oncology imaging technologies.
domain founded_year HQ Location
Epigenetic tests for personalized cancer assessment and treatment.
domain founded_year HQ Location
Antibodies, small molecules, and vaccines are developed for neurodegenerative diseases.
domain founded_year HQ Location
Genomic tests for urologic cancers are developed and commercialized.
domain founded_year HQ Location
Diagnostics and therapeutics for neurodegenerative disorders are developed.
domain founded_year HQ Location
Small molecule drugs and imaging agent for GI disorders
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Progenics

Frequently Asked Questions about Progenics

When was Progenics founded?

Progenics was founded in 1988 and raised its 1st funding round 18 years after it was founded.

Where is Progenics located?

Progenics is headquartered in United States.

How many employees does Progenics have?

As of Dec 31, 2020, the latest employee count at Progenics is 53.

What does Progenics do?

Progenics Pharmaceuticals was founded in 1988 in the United States and operates in the oncology sector of pharmaceuticals. Imaging agents and targeted radiotherapeutics are developed, focusing on prostate-specific membrane antigen (PSMA)-targeted technologies for prostate cancer, including antibody drug conjugates and small molecule agents. Additional pipeline assets include Azedra for malignant pheochromocytoma and paraganglioma treatment. The first commercial product, Relistor, is approved for opioid-induced constipation.

Who are the top competitors of Progenics?

Progenics's top competitors include ImaginAb, AC Immune and MDxHealth.

How many acquisitions has Progenics made?

Progenics has made 3 acquisitions, including AZEDRA, EXINI Diagnostics, and Molecular Insight Pharmaceuticals.

Who are Progenics's investors?

Progenics has 2 investors. Key investors include HHS, and Lantheus.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available